Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Biotage in connection with RWK Bidco’s public tender
Mandate

Vinge advises Biotage in connection with RWK Bidco’s public tender

April 22, 2025 M&A

On 22 April 2025, RWK Bidco AB, a newly formed company indirectly wholly owned by KKR Funds, announced a public tender offer to the shareholders in Biotage AB to tender all ordinary shares in Biotage to RWK Bidco at a price of SEK 145 in cash per ordinary share.

Biotage is a global supplier and solutions partner to a wide range of customers within drug discovery and development and analytical testing. Headquartered in Sweden, Biotage operates globally serving over 80 countries. The company is listed on Nasdaq Stockholm. The offer values Biotage to approximately SEK 11,607 million based on the total number of ordinary shares in Biotage.

Vinge’s team mainly consists of Dain Hård Nevonen, Joel Magnusson, Benjamin Vafaeian, Lovisa Jonassen, Vilma Henricsson, David Olander and Emelie Schoning.

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

 Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

 Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025